UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2025
Commission file number: 001-40231
Universe Pharmaceuticals INC
265 Jingjiu Avenue
Jinggangshan Economic and Technological Development
Zone
Ji’an, Jiangxi, China 343100
+86-0796-8403309
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Adjournment of Annual General Meeting
On August 26, 2025, Universe
Pharmaceuticals INC (the “Company”) convened the 2025 annual general meeting of shareholders (the “2025 Annual General
Meeting”). However, due to a lack of quorum, the 2025 Annual General Meeting was adjourned to September 2, 2025, at 10:00 a.m.,
Beijing Time at 265 Jingjiu Avenue, Jinggangshan Economy and Technology Development Zone, Ji’an City, Jiangxi 343100, the People’s
Republic of China.
SIGNATURES
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
| |
Universe Pharmaceuticals INC. |
| |
|
| Date: August 26, 2025 |
By: |
/s/ Gang Lai |
| |
|
Gang Lai |
| |
|
Chief Executive Officer |
